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Evidence is increasing that the hepatitis C virus (HCV) 
is neurovirulent. Neuroimaging studies suggest that 
individuals with HCV infection show alterations 
in the structure and function of several neural sys-
tems, most notably the frontostriatal circuits. Several 
studies also demonstrated evidence of cognitive 
impairment across a variety of ability areas in about 
30% to 40% of HCV-infected individuals. Although 
certain comorbidities (eg, substance abuse, HIV coin-
fection, neuropsychiatric symptoms) may increase 
the risk of neurocognitive deficits in HCV-positive 
individuals, it appears that neurocognitive impair-
ment is present in HCV-positive individuals without 
significant comorbidities. We provide an overview of 
the neurocognitive effects of HCV infection and pres-
ent empirical evidence examining episodic memory 
abilities in HCV-positive individuals. The results of 
our study indicate that HCV-positive individuals have 
difficulties learning new verbal and visual informa-
tion, but are nevertheless able to retain and recognize 
the information they have learned. Implications for 
everyday functioning are discussed.
Introduction
It is estimated that about one third of people with chronic 
hepatitis C virus (HCV) infection experience neurocog-
nitive impairments, which can be independent of the 
severity of liver disease, hepatic encephalopathy, viral 
load and genotype, and comorbid drug abuse [1,2]. In 
this article, we review relevant evidence supporting neu-
rovirulence, specific brain systems affected, comorbidities 
(eg, substance abuse, HIV-coinfection, neuropsychiatric 
factors), HCV treatment effects, commonly affected neu-
ropsychologic domains, and implications for daily living. 
We also report novel preliminary data regarding the pro-
file of HCV-associated deficits in learning and memory.
Neurovirulence of HCV 
Evidence is increasing that HCV is neurovirulent. The 
exact mechanism by which HCV enters the central nervous 
system is unknown; however, it was postulated that HCV 
may cross the blood–brain barrier via infected monocytes 
using a Trojan horse mechanism [3]. The hypothesis that 
HCV can cause brain dysfunction is supported by replica-
tion of HCV in the astroglia of patients with AIDS [4], 
detection of HCV RNA in brain tissue [5], and demon-
stration of metabolic changes resembling HIV infection 
[6]. A study showed that among HCV/HIV coinfected 
persons, immunoreactivity occurred in the astroglia of 
white matter and (to a lesser extent) in macrophages and 
microglia [7], whereas another study detected HCV RNA 
primarily in microglia and macrophages and to a lesser 
degree in astrocytes [8]. It remains unclear if neurocog-
nitive and neuropsychiatric symptoms of HCV-infected 
individuals relate to the direct effects of HCV infection 
on the brain or to a nonspecific reaction of brain cells to 
mediators of inflammation (eg, cytokines) [3].
Brain Systems Affected in HCV
Neuroimaging studies suggest that HCV-positive indi-
viduals show altered structure and function of several 
neuronal systems, including the frontal neocortex, basal 
ganglia, and connecting white matter tracts [6,9]. Mag-
netic resonance spectroscopy (MRS) studies usually 
measure four compounds thought to be the most reliable: 
N-acetylaspartate (NAA), a marker of neuronal integrity; 
choline (Cho), a measure of cell membrane turnover and 
lipid changes; myo-Inositol (Ins), a possible indicator of 
glial proliferation and/or osmolar changes; and creatine 
(Cr), an indicator of high-energy stores that is often used 
as a relative standard for other metabolites [10]. 
Similar to findings in HIV disease, higher Cho/Cr 
ratios are found in the white matter and the basal gan-
glia of HCV-positive individuals compared with healthy 
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volunteers, suggesting that HCV infects the brain 
directly, activates microglia via peripherally derived 
cytokines, or both [6]. MRS studies also found elevated 
metabolic markers of neuronal injury and neuroinflam-
mation in the basal ganglia and frontal white matter 
of persons with HCV [11]. Reductions in the NAA/Cr 
ratio in the frontal gray matter were demonstrated in 
HCV-infected patients, but no changes were observed 
for the Cho/Cr ratio [9]. Furthermore, increased Cho 
and decreased NAA were demonstrated in the white 
matter of HCV-positive patients compared with sero-
negative subjects [12]. Most recently, Forton et al. [13] 
found a significant increase in the Ins/Cr ratio in a 
group of HCV-positive individuals with mild liver dis-
ease compared with healthy adults.
Using single photon emission tomography, alterations 
of mesencephalic/hypothalamic serotonin and striatal 
dopamine transporter binding were observed in some 
HCV-positive patients [14]. A study using positron emis-
sion tomography showed decreased glucose metabolism 
in the limbic association cortex of HCV-positive patients 
compared with healthy adults [15]. Future studies of 
brain functioning in HCV-infected individuals would 
benefit from examining the integrity of white matter 
tracts using diffusion tensor imaging. Also, structural 
MRI would provide information regarding volumes of 
gray and white matter overall, volumes of specific regions 
(eg, basal ganglia structures, hippocampus), and volume 
of abnormal white matter that may reflect foci of HCV-
induced inflammation. Finally, functional MRI studies 
would shed light on the brain activity of HCV-positive 
persons while performing cognitive tasks. Other possibili-
ties include studies of cortical thickness, which appears to 
be reduced in other infectious diseases (eg, HIV [16]), and 
multimodal approaches [17].
Cognitive Dysfunction in HCV
Consistent with the brain imaging data, several stud-
ies also demonstrated evidence of cognitive impairment 
across a variety of ability areas among HCV-positive 
individuals [3]. However, the severity of impairment and 
the specific cognitive domains affected vary somewhat 
across the literature [18]. Notably, the pattern of cognitive 
deficits reported among individuals infected with HCV 
may be influenced by the severity of liver disease (eg, liver 
fibrosis, decompensated cirrhosis), other comorbidities (eg, 
substance use disorders, HIV infection, neuropsychiatric 
symptoms), and whether the HCV-positive individual has 
initiated treatment for HCV (Table 1). 
Severity of liver disease
HCV causes a fluctuating chronic hepatitis that may 
progress to cirrhosis, hepatocellular carcinoma, and ulti-
mately, liver failure. It is well established that advanced 
forms of liver disease are accompanied by overt and 
global cognitive deficits (ie, hepatic encephalopathy [19]). 
Hepatic encephalopathy symptoms include altered level of 
consciousness, asterixis, spatial disorientation, and visual 
hallucinations. Nevertheless, HCV-associated neurocog-
nitive impairment also was found among HCV-positive 
individuals without marked liver disease, in the absence 
of hepatic encephalopathy. This is not to suggest that 
more advanced liver disease does not worsen neurocogni-
tive impairment. For instance, a study by Hilsabeck et al. 
[20] showed greater cognitive dysfunction in those with 
greater fibrosis stage, but similar cognitive performance 
between individuals with and without cirrhosis. In the 
context of chronic HCV infection, comparing individu-
als who had cirrhosis without decompensation with those 
who had cirrhosis with prior decompensations revealed 
that those with decompensated cirrhosis were impaired 
in the domains of attention, executive function, and 
motor skills, whereas individuals without cirrhosis and 
those with mild chronic HCV performed similarly within 
normal levels [21]. Importantly, several studies found cog-
nitive impairment in HCV-positive individuals without 
severe liver disease [6,12]. 
Substance use disorders
The prevalence of substance use disorders among HCV-
infected individuals is high, and intravenous drug use 
(IVDU) is the primary risk factor for chronic HCV 
infection (eg, 60%–70% of persons with chronic HCV 
infection indicate a history of IVDU). Few studies have 
assessed the effect of substance abuse on cognitive func-
tioning in chronic HCV, and the most notable have found 
little [22•] to no [23] significant differences between 
HCV-positive individuals with and without history of 
substance use disorders. 
HIV coinfection
Because viral transmission routes overlap somewhat (eg, 
IVDU), many HCV-positive individuals are also HIV-
infected. Coinfected individuals show impairment on 
measures of executive function, psychomotor speed, and 
global cognitive function [24–26]. In a recent study com-
paring coinfected individuals with HIV-monoinfected 
individuals, coinfected individuals were more likely to be 
classified as neuropsychologically impaired and had par-
ticular impairments in learning and recall [27].
Neuropsychiatric symptoms
High levels of general psychologic distress and self-reported 
mood disturbance appear prevalent among HCV-positive 
individuals [28]. Fatigue is the most frequently reported 
symptom, with prevalence estimates ranging from 53% to 
70% [29]. Approximately 28% to 50% of HCV-infected 
individuals report elevated symptoms of depression, 
whereas symptoms of anxiety are present in 18% to 41% 
of the population [30]. Examples of reported associations 
between neuropsychiatric symptoms and cognition include 
self-reported depressive symptoms with sustained atten-
tion, and moderate fatigue with general slowing on 
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Table 1. Selected studies of cognitive dysfunction in individuals with chronic hepatitis C
Study Sample Findings
Forton et al. [11] 27 HCV+ (13 IVDU), 16 cleared HCV 
(8 IVDU), and 29 HC.
HCV+ uncleared had worse concentration and 
psychomotor speed. No differences in working 
memory and attention.
Kramer et al. [23] 100 HCV+ (25 cirrhotic) and 100 HCV–. 
Other comorbidities: IDVU (23 HCV+).
16% of HCV+ individuals had abnormal P300 
latencies (measure of overall cognitive func-
tioning). No association with disease stage.
Hilsabeck et al. [20] 44 HCV+ without medical comorbidities, 
22 HCV+ with medical comorbidities, 14 
HCV– with other liver diseases. Fibrosis stage: 
mild (15), moderate (4), severe (13), cirrhosis 
(34). Comorbidities included alcohol hepatitis 
(10), HIV (8). Other liver disease included 
HBV (5), cryptogenetic (4).
Deficits in attention, learning, psychomotor 
speed, and mental flexibility. Visuoconstruc-
tion and recall normal. Greater impairment 
was associated with greater fibrosis stage. 
HCV+ and HCV– with other liver diseases 
performed similarly.
Hilsabeck et al. [31] 21 chronic HCV+ (7 cirrhotic). Other 
comorbidities: HIV (2), type 2 diabetes 
(3), alcoholic hepatitis (4), HCV antiviral 
therapy (5), IVDU (15).
Impairment in visuoconstruction abilities, 
learning, recall, complex attention, and 
psychomotor speed. 
Cordoba et al. [21] 40 HCV+ mild, 40 HCV+ with compensated 
cirrhosis, 40 HCV+ with decompensated 
cirrhosis, and 40 HC. Other comorbidities: 
arterial hypertension (11), type 2 diabetes 
(14), IDVU (3).
Decompensated cirrhotic were significantly 
more impaired on attention, executive 
function, and motor abilities than other 3 
groups. No impairment on learning, recall, or 
visuoperceptive functioning.
Weissenborn et al. [9] 30 HCV+ (15 with mild fatigue, 15 with 
moderate fatigue), 15 HC.
Moderately fatigued patients performed sig-
nificantly worse on attention, learning, and 
executive function. Recall and visuoconstruction 
abilities appear to remain intact.
Fontana et al. [18] 201 HCV+ (76 cirrhotic). Comorbidities: IDVU 
(92), alcohol use disorder (104), drug use 
disorder (78), lifetime depressive disorder (30), 
lifetime anxiety disorder (22), type 2 diabetes 
(50), hypertension (56).
33% of subjects had evidence of impairment 
on verbal recall and working memory. 
Normal on psychomotor speed, executive 
function, and verbal fluency. Impairment not 
related to liver fibrosis.
McAndrews et al. [12] 37 HCV+ (11 endorsed depressive symptoms), 
42 HC. Fibrosis stage: mild (9), moderate (17), 
severe (11), cirrhosis (0).
HCV+ individuals have deficits on learning, 
attention, recall, psychomotor speed. Mental 
flexibility appeared intact.
Bieliauskas et al. [40] 100 HVC+ with advanced liver fibrosis and 
nonresponders to interferon therapy (33 
cirrhotic). No comorbidities reported.
44% of subjects categorized as impaired. Learn-
ing, recall, and executive function were most 
affected domains, whereas motor skills and 
verbal fluency were less affected.
Fontana et al. [37•] 177 HCV+ with advanced liver fibrosis and 
nonresponders to interferon therapy (65 
cirrhotic). Other comorbidities: type 2 
diabetes (44).
32% of subjects were cognitively impaired at base-
line. Deficits in verbal recall and working memory. 
Psychomotor speed, visuomotor tracking, verbal 
fluency, and executive functioning intact. 
Karaivazoglou et al. [41•] 32 HCV+ (7 cirrhotic), 29 HBV+ 
(6 cirrhotic), 20 HC.
HCV+ worse than HC on verbal learning and recall. 
HCV+ and HBV+ similarly impaired. Psychomotor 
speed, verbal fluency, and attention appeared 
intact. In HCV+, cognitive dysfunction was associ-
ated with severity of liver disease.
Forton et al. [13] 16 HCV+ with mild liver disease (10 IDVU). 
16 HC.
Significant correlations between elevated myo-
inositol/creatine and longer working memory 
reaction times.
Huckans et al. [22•] 39 HCV+ (SUD+), 24 HCV+ (SUD–), 56 HC. 
Other comorbidities: mood disorder (25), 
posttraumatic stress disorder (12), type 2 
diabetes (9), hypertension (18).
HCV+/SUD– worse than HC on learning, attention, 
and mental flexibility but only HCV+/SUD+ worse 
than HC on psychomotor speed. Verbal fluency, 
motor skills, and visuomotor abilities intact.
HBV—hepatitis B virus; HC—healthy controls; HCV—hepatitis C virus; IVDU—intravenous drug use; SUD—substance use disorder.
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electroencephalogram [9,11]. In contrast, other studies 
have not found differences in neuropsychologic perfor-
mance between HCV-positive individuals with high and 
low levels of self-reported neuropsychiatric disturbance, or 
have demonstrated a relationship between fatigue and gen-
eral cognitive functioning [31,32]. Thus, neuropsychiatric 
symptoms among HCV-positive individuals may contribute 
to neurocognitive dysfunction; however, it appears unlikely 
that neuropsychiatric symptoms alone account for the neu-
rocognitive deficits associated with HCV.
HCV treatment
Treatment of HCV with pegylated interferon-α and 
ribavirin was hypothesized to induce neurocognitive 
impairment, based on research showing a marked increase 
in neuropsychiatric complaints during treatment [33]. 
However, self-reported cognitive complaints do not relate 
strongly to objective, performance-based deficits in neuro-
psychologic functioning [34]. Indeed, research regarding 
objective cognitive declines during antiviral treatment 
produced mixed results, perhaps from variability in study 
design, duration of follow-up, and outcome measures. 
Despite these limitations, our review of literature suggests 
that mild objective impairments may emerge during the 
first few months of therapy, but appear transient in nature 
and tend to normalize by 24 weeks [35,36]. In the largest 
and most comprehensive study, no significant cognitive 
declines were observed in 177 HCV-positive patients on 
treatment for 24 weeks, 57 of whom were followed as 
long as 48 weeks [37•]. Other groups report mild, long-
term improvements in cognitive function in individuals 
who achieve sustained viral response [38]. Considering 
these data, it may be argued that the possibility of mild, 
transient declines in some aspects of cognitive functioning 
associated with treatment does not outweigh the con-
siderable health and quality-of-life benefits of successful 
antiviral therapy.
Neurocognitive Impairment by Domain 
Attention
Attention refers to several different capacities or processes 
related to how an individual becomes receptive to stimuli 
and how he or she may process or focus on such information 
[39]. Many subcomponent attentional processes exist; some 
of the most frequently studied aspects are focused attention 
(ie, ability to respond to a specific stimulus presented on a 
particular sensory modality), sustained attention/vigilance 
(ie, capacity to maintain attention to a specific stimulus over 
time), selective attention (ie, capacity to maintain attention 
in the face of distracting or competing stimuli), and divided 
attention (ie, ability to respond simultaneously to multiple 
tasks) [39]. The most striking study of attention deficits in 
HCV infection showed that up to 82% of HCV-positive 
individuals with other medical comorbidities had impaired 
performance on tests of sustained attention, and 59% 
showed impairment on tests of selective attention, whereas 
49% of HCV-positive individuals without other medical 
comorbidities had impairment on sustained attention and 
25% had impairment on selective attention [20]. In a similar 
HCV-positive group studied using slightly different meth-
ods, 38% of individuals were impaired on selective attention 
[31]. Another study found selective attention deficits only in 
HCV-positive individuals with decompensated cirrhosis [21]. 
However, other studies found attention deficits in individu-
als with mild HCV infection and no comorbidities, including 
difficulties with focused and divided attention, sustained 
attention, and selective auditory attention [9, 13,22•]. 
Psychomotor speed
Psychomotor speed refers to the amount of time it takes 
a person to process a signal, prepare a response, and exe-
cute that response [39]. It is a broad, often amorphous, 
construct that is closely related to attention, because 
slowed processing speed sometimes underlies attentional 
deficits [39]. Several studies assessed this domain in 
HCV and the results are somewhat mixed: some studies 
show psychomotor speed to be intact among HCV-posi-
tive individuals [9,12,18,21], whereas others suggest 
that psychomotor speed is one of the most affected 
neurocognitive domains [11,20,31]. In one study, 25% 
of HCV-positive individuals and 41% of HCV-positive 
individuals with other comorbidities were impaired 
on a basic processing-speed measure (ie, Trial Making 
Test, part A) [20]. Impairments in this domain may be 
particularly susceptible to comorbidities (eg, substance 
dependence and chronic medical conditions) [20,22•]. 
Executive function
Executive functions encompass a broad range of “higher-
order” abilities including those responsible for planning, 
mental flexibility, abstract reasoning, concept formation, 
initiating appropriate actions, and inhibiting inappropri-
ate actions. About 30% of HCV-positive individuals 
were impaired on a test of mental flexibility, abstract 
reasoning, and concept formation [40]. Similarly, some 
studies found that HCV-positive persons had deficits in 
verbal response inhibition, reasoning, and mental flex-
ibility [21,22•]. Other studies found these abilities intact 
among HCV-positive individuals [12,18,37•]. 
One aspect of executive function that is sometimes 
considered an independent domain is verbal fluency, 
which is the ability to rapidly produce words, in speech or 
writing, within a certain time. Among HCV-positive indi-
viduals, only one study found minor impairment, whereas 
four other studies found this domain intact in individuals 
with HCV infection [18,21,37•,41•]. Cordoba et al. [21] 
found verbal fluency impairments among HCV-posi-
tive individuals with decompensated cirrhosis. Although 
several studies assessed different aspects of executive 
function, future studies of HCV-positive individuals 
would benefit from examining performance on measures 
of other executive functions, such as planning, decision-
making, and response inhibition.
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Motor skills
Few studies have assessed motor skills (eg, finger tapping, 
fine motor coordination) in HCV infection. Three studies 
found impairments in this domain: Cordoba et al. [21], 
Vigil et al. [42], and Bieliauskas et al. [40]. Interestingly, 
although the first two studies used the same test (the 
Grooved Pegboard Test) to assess motor skill, Cordoba et 
al. [21] found motor deficits only in HCV-positive indi-
viduals with decompensated cirrhosis, whereas Vigil et al. 
[42] found impairments in relatively healthy HCV-positive 
individuals. Bieliauskas et al. [40] found that about 15% 
to 18% of HCV-positive individuals with advanced liver 
fibrosis have impaired motor skills.
Visuoconstruction abilities
Visuoconstruction abilities involve the coordination of 
fine motor skills with spatial abilities [39]. These func-
tions embrace two large classes of activities: drawing 
and building or assembly [39]. Most studies evaluating 
visuoconstruction skills in HCV have examined draw-
ing; of the studies assessing these skills, only one reported 
visuoconstruction impairments in 9% of HCV-positive 
individuals [31]. Future studies assessing visuoconstruc-
tion abilities in HCV-positive individuals should include 
building and assembly tasks, which provide further infor-
mation regarding visuoconstruction and motor abilities.
Memory
Investigations of memory functioning in HCV typically 
focused on episodic memory, which refers specifically to 
memory for experienced events and includes information 
about the content of the event (eg, “what” was learned 
during the episode, including objects and word-lists) 
and the contextual details of the event (eg, “when” and 
“where” the episode occurred, including time, location, 
and source) [43]. Successful episodic memory involves 
three separable but strongly interrelated processes: encod-
ing, consolidation, and retrieval. Encoding is the process 
by which new information is learned, and consolidation 
refers to the process of storing that information over time. 
Retrieval is the capacity to effectively access the stored 
information after a delay. Poor memory performance can 
result from a disruption of these processes individually 
or in combination; therefore, they are methodologically 
evaluated separately. Furthermore, examination of the 
profile of memory performance can provide information 
about the integrity of the underlying neural systems. 
Measures of encoding typically represent the amount 
of information that an individual learns during one or 
more learning trials involving presentation of novel infor-
mation. A total learning score, summed across multiple 
learning trials, is particularly informative for indicating 
how much new information has been acquired. Retrieval 
is a complex process that is measured in two ways: free 
recall and recognition. Free recall is a more demand-
ing task that requires the individual to search the stored 
information and correctly access it on demand; retrieval 
failures may occur even when information was success-
fully learned and stored. On the other hand, recognition 
memory is an easier task in which previously learned 
information is presented alone (ie, yes/no recognition) 
or paired with a foil (ie, forced-choice recognition), and 
the individual indicates whether he or she recognizes it. 
Because consolidation is not measured directly, the rela-
tive ease of the recognition task inferentially provides a 
measure of how much of the learned information was 
stored over time. That is, poor recognition performance 
relative to learning suggests that learned information was 
forgotten over the delay; this outcome is typically observed 
when hippocampal structures are damaged. In contrast, 
poor recall performance relative to better recognition sug-
gests a retrieval deficit, in which the individual has not 
forgotten the information but has difficulty accessing it 
without a cue; this pattern is associated with dysfunc-
tion in the frontostriatothalamocortical circuits that are 
thought to underlie successful retrieval.
Several studies that included measures of verbal learn-
ing and memory found HCV-associated impairments in 
these domains, suggesting that the impairments are rather 
robust among HCV-positive patients. For example, Hilsa-
beck et al. [20] found that 46% of HCV-positive patients 
with comorbidities were impaired on learning and 23% 
were impaired on recognition; 21% of HCV-positive 
patients without comorbidities were impaired on learn-
ing and 14% on recognition; and 15% of individuals with 
other liver disease were impaired on learning and 15% on 
recognition. When replicating these results on a different 
sample, investigators found that 16% of HCV-positive 
individuals with different comorbidities were impaired on 
learning and 14% had impaired recall [31]. 
In a recently published article, Huckans et al. [22•], 
found that 33% of HCV-positive individuals with a his-
tory of substance dependence were impaired on a test of 
verbal learning, whereas 44% were impaired on tests of 
visuospatial learning. Interestingly, among HCV-posi-
tive individuals with no history of substance dependence, 
42% were deemed impaired on verbal learning and 46% 
on visuospatial learning. Karaivazoglou et al. [41•] also 
found that HCV-positive individuals performed worse 
than those who were seronegative on measures of verbal 
learning and recall; however, they found no differences 
in these measures between HCV-positive individuals and 
individuals infected with the hepatitis B virus. In contrast, 
Weissenborn et al. [9] found that HCV-positive individu-
als with moderate fatigue performed worse on learning 
than healthy controls, but those with mild fatigue per-
formed similarly to controls. They found no differences in 
the recall domain. 
Learning and Memory Profiles in HCV 
Infection: A Data-based Examination
As reviewed above, significant evidence exists of HCV-
associated episodic memory impairment in the literature; 
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however, no studies have examined the profile of memory 
deficits in an HCV-infected population. Delineation of a 
memory profile could enhance understanding of the effect 
of HCV on the brain, and may even have clinical utility 
in terms of informing detection and remediation of daily 
functioning difficulties. Accordingly, we present data on 
the profile of episodic memory functioning in a cohort 
of 43 HCV-positive individuals relative to a group of 49 
demographically comparable, healthy participants (HCV-
negative persons). We excluded individuals with a history 
of severe psychiatric illness, head trauma with loss of con-
sciousness greater than 30 minutes, neurologic disease, 
or current substance abuse or dependence (ie, alcohol, 
cocaine, opioid, marijuana, stimulants, hallucinogens). 
Demographic and clinical characteristics of the study par-
ticipants are presented in Table 2. 
All participants were administered the Hopkins Verbal 
Learning Test–Revised (HVLT-R) and the Brief Visuospatial 
Memory Test–Revised (BVMT-R) as part of a larger neuro-
psychologic battery [44,45]. Briefly, the HVLT-R consists of 
three groups of four (nonconsecutive) semantically related 
words, which are read aloud at about 2-second interstimulus 
intervals. The HVLT-R includes three consecutive learning 
trials, a free-recall trial after a delay of 20 to 25 minutes, 
and a recognition trial (24 words consisting of 12 target 
words from the original list and 12 nontarget words). Six of 
the 12 nontarget words are semantically related to words on 
the original list. The BVMT-R consists of three consecutive 
learning trials involving presentation of a display comprising 
six geometric designs, a free-recall trial after a delay of 20 
to 25 minutes, a recognition trial with 12 designs consisting 
of six target designs and six nontarget designs, and a copy 
trial to rule out visual deficits. The outcome variables for 
both tests were learning (the numbered of correctly recalled 
words/figures on trials 1 to 3), recall (the total correctly 
recalled words/figures on the free recall), and recognition 
(the number of correct recalled words/figures after being 
presented one more time). Raw scores for each test variable 
were converted into demographically adjusted T-scores. 
Compared with seronegative participants, HCV-
infected individuals had significantly lower T-scores on 
learning measures for the HVLT-R (P = 0.04, Cohen’s 
d = -0.43) and the BVMT-R (P = 0.04, d = -0.44). Par-
ticipants in both groups performed similarly on measures 
of delayed recall and recognition for both tests. Figure 
1 displays the poorer learning performance in the HCV-
positive group relative to healthy controls on the HVLT-R 
and BVMT-R, which is in contrast to the comparable 
delayed recall and recognition performance. Notably, 
a significant difference between the groups was also 
observed on the Retrieval Index of the HVLT-R (P = 0.01, 
d = -0.60), which is a measure of the discrepancy between 
delayed free recall and recognition performance. 
These findings provide further evidence regarding the 
profile of learning and memory performance in HCV infec-
tion. The consistent finding of impaired learning across 
Table 2. Demographic characteristics of study participants
Variable HCV+, n = 43 HCV–, n = 49 
Age, mean (SD) 45.3 (9.7) 43.0 (9.7)
Education, mean (SD) 12.4 (2.2) 12.9 (2.3)
Ethnicity white, % (n) 74% (32) 67% (33)
Gender male, % (n) 56% (24) 61% (32)
Major depressive disorder, % (n)
Current 3% (1) 2% (1)
Lifetime 38% (16) 28% (14)
Substance dependence, % (n)
Alcohol 46% (20) 6% (3)
Cocaine 49% (21) 2% (1)
Marijuana 27% (12) 6% (3)
Stimulants 35% (15) 0%
Opioids 32% (14) 0%
Hallucinogens 11% (4) 0%
HCV characteristics, median (IQR)
HCV RNA serum, IU/mL 5.9 (5.0, 6.2) NA
Total bilirubin, mg/dL 0.7 (0.4, 0.9) NA
Albumin, g/dL 0.4 (3.8, 4.2) NA
AST-to-platelet ratio index 0.4 (0.3, 0.9) NA
AST—aspartate transaminase; HCV—hepatitis C virus; IQR—interquartile range; NA—not applicable; SD—standard deviation.
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verbal and visual modalities suggests that HCV-positive 
individuals have difficulty acquiring new information, 
which may be evidence of deficient encoding. Although 
findings in the literature regarding memory performance 
in HCV infection are mixed, our results suggest compara-
ble performance of the HCV-positive participants relative 
to healthy individuals on delayed recall and recognition. 
However, the observed differences on the Retrieval Index 
of the HVLT-R revealed a greater discrepancy between 
delayed recall and recognition performance in the HCV-
positive participants relative to the healthy participants, 
which may suggest that HCV-positive individuals had 
more difficulty freely recalling the information they had 
learned but were better able recognize that information 
when provided with a structure format. Although infer-
ential, the poorer performance observed on measures 
of learning and the retrieval index in the HCV-positive 
group is consistent with deficient strategic encoding and 
retrieval processes that rely on frontostriatal systems [46], 
which are purportedly involved in HCV infection. The 
potential clinical implications of these findings include 
emphasizing the importance of recommendations for 
mnemonic compensatory strategies for HCV-positive 
patients, particularly regarding adherence to their medi-
cation regimen (eg, use of written instructions, calendars, 
alarms, pillboxes). 
Implications for Daily Living 
In general, HCV-infected individuals have diminished 
health-related quality of life (HRQOL) compared with 
healthy adults [47]. With regard to the association between 
HRQOL and cognitive impairment among HCV-positive 
individuals, some studies found no associations between 
cognitive functioning and HRQOL [38], whereas other 
studies found small but significant correlations between 
these two factors. Specifically, poorer HRQOL is associ-
ated with worse performance on an electrophysiologic test 
of cognition [23], worse attention [21], and worse global 
neurocognitive performance [40]. 
In contrast to HRQOL, few studies have examined the 
independent performance of activities of daily living in this 
population. A study from our group found that, compared 
with HCV-negative individuals, HCV-positive individu-
als reported significantly greater declines in instrumental 
activities of daily living (IADL) (eg, managing finances, 
medication adherence, employment), and physical activities 
of daily living (PADL) (eg, bathing, laundry, home repairs) 
[42]. HCV-positive individuals with impaired psychomotor 
speed reported significantly greater IADL declines, whereas 
impaired fine-motor coordination was associated with 
declines in both IADLs and PADLs. Moreover, impaired 
psychomotor speed predicted IADL declines, whereas fine-
motor coordination impairment predicted PADL declines. 
In general, HCV-positive persons have decreased HRQOL, 
and HCV-positive individuals with neuropsychologic 
impairment are at greater risk of poorer functional out-
comes, including PADLs and IADLs.
In terms of medication adherence, several studies 
examined adherence to HCV treatment [48]. Using self-
report, 69% to 98% of HCV-positive individuals reported 
being adherent to their medications, whereas 74% to 92% 
were adherent when measured by electronic devices [48]. 
HCV-positive individuals tend to be more adherent during 
the first 4 weeks of treatment and decrease adherence dur-
ing the course of treatment. To our knowledge, no study 
has assessed the relationship between nonadherence and 
cognition in individuals with HCV infection. 
Conclusions
In summary, evidence from brain tissue, imaging, and 
neuropsychologic studies support the neurovirulence of 
HCV infection. Findings from the data presented here 
indicate that HCV-positive individuals have learning defi-
cits although they have normal recall and recognition of 
Figure 1. A, Brief Visuospatial Memory Test–Revised (BVMT-R) and B, Hopkins Verbal Learning Test–Revised (HVLT-R): learning, recall, and 
recognition measures in hepatitis C virus (HCV)–positive and HCV-negative groups (*P < 0.05).
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new information. HCV affects HRQOL and ADLs, and 
these impairments may be driven by cognitive dysfunction. 
Although several studies reported problems with medica-
tion adherence among HCV-positive persons, it is unknown 
whether cognitive impairment is related to nonadherence, 
as was shown in HIV infection [49,50]. Thus, future stud-
ies examining adherence to HCV treatment should assess 
the role of cognitive dysfunction in nonadherence. As with 
many conditions that cause subtle neurocognitive impair-
ment, understanding the contributions of various cofactors 
(eg, substance dependence, neuropsychiatric symptoms) to 
neurocognitive impairment in HCV is critical. Also, future 
studies would benefit from additional assessments of every-
day functioning (eg, financial management, driving) not 
only with self-report but also with laboratory measures, 
which have greater ecological validity. Importantly, knowl-
edge is lacking regarding the vocational functioning of 
HCV-positive individuals and how neurocognitive impair-
ments may moderate these abilities. 
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